Background: Histologic prognostic factors have been described for nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). This study examines histologic and immunophenotypic variants in a clinical trial for pediatric NLPHL. 
INTRODUCTION

Nodular lymphocyte predominant (LP) Hodgkin lymphoma (NLPHL)
represents 5-10% of Hodgkin lymphoma (HL) with a male predominance and typical presentation of low-stage disease without B symptoms. NLPHL is usually slow-growing and responsive to therapy, but may be more aggressive. 1 Children's Oncology Group trial AHOD03P1 was designed to test the efficacy of stage-directed reduced-therapy treatment of low-risk NLPHL in young people, with stage IA or IIA disease. 1 At the time of protocol design, there had been recent reports of a relatively new subtype of classical HL (CHL) mimicking NLPHL, lymphocyte-rich CHL. 2 These were noted in one large series to constitute about 34% of cases previously diagnosed as NLPHL. 3 The protocol was designed with a "watch and wait" component for totally resected stage IA disease present in a single node. Out of concern that this would not be appropriate for CHL, all cases were required to have immunohistochemical (IHC) staining performed, and all were subjected to rapid pathology review.
The morphology and immunohistochemistry of NLPHL show nodules of small B cells with admixed larger neoplastic LP cells (Fig. 1A) . 4 T-cell-rich (T-cell-rich large B-cell lymphoma like, pattern E) and diffuse B-cell-rich patterns (moth-eaten, pattern F). 6 Variant histology has been incorporated into novel grading schemes for NLPHL as it has been tentatively associated with adverse features. [7] [8] [9] [10] Positivity for CD30 has been noted in up to 28% of NLPHL, usually focal or heterogeneous and more frequent in the presence of EpsteinBarr virus (EBV). [11] [12] [13] [14] CD30 may provide a target for anti-CD30 therapeutic antibodies in the rare CD30-positive cases that relapse. 15 IgD expression has been described to be frequent in young male patients and to be associated with the presence of large B cells in the extranodular regions. 7, 16 In this study we examine the histologic pat- or bulky disease were excluded from the study.
Histology
Stained and unstained slides from fixed, paraffin-embedded lymph node biopsies were histologically reviewed and assessed according to and/or CD23 were scored in some cases, although not stressed for diagnosis at the time of protocol design. Most cases had been vetted by expert hematopathologists prior to enrollment in the study. All submitted slides were reviewed prospectively and diagnoses confirmed on enrollment in a rapid review.
Submitted CD30 stains were examined, staining of all cases described as positive at the treating institution was repeated, and additionally was repeated for all other cases with unstained slides. Final scoring of CD30 was based on our review of one or more slides. For most cases, CD20 staining was also repeated. IgD was performed on all cases that had available unstained slides. Repeat IHC stains were performed on an automated immunostainer (Ventana Medical Systems,
Tucson AZ), with monoclonal antibodies CD30, CD20, CD3, and antiIgD (Cell Marque, Rocklin, CA) using standard technique.
All cases were categorized based on morphology into five categories, corresponding to the patterns reported by Fan et al. 6 Each case was assessed for percent involvement by each histologic type, and then condensed to a score of 0-2 as described in the statistical section.
Treatment strategy
Patients 
Statistics
For each histologic type, A-E, the proportion of involvement of avail- 
RESULTS
Details of patient characteristics, therapy, and overall clinical outcomes have been previously reported. 1 Briefly, 188 patients were enrolled, 183 were eligible, and 178 were evaluable for analysis in the clinical report of this protocol; 5 patients who had protocol deviations were excluded. Among these, 168 cases were available for further histopathologic evaluation at the end of protocol (slides were no longer available in 10 cases). The mean age at enrollment was 12.3 years (range 4.2-20.7), and 85% were males. The most common sites of involvement were lymph node groups in the head and neck, axilla, or groin. Mediastinal involvement was rare (n = 7, 3.8%). A diagnosis of NLPHL was confirmed by central review for each case. EFS at 5 years was 85.5% and overall survival (OS) at 5 years was 100%.
Fifty-nine (35.1 %) cases showed only typical nodular or nodular and serpiginous histology (types A and B; Fig. 1 C-F) . The remainder Fig. 2E ). There was a total of five patients (three patients with score 1 and two patients with score 2) with type F, and these were younger than other patients, 5.0 ± 0.8 and 5.0 ± 0.4 years, respectively, versus 12.3 ± 4.0 years for other patients, P = 0004.
Type C was associated with decreased EFS (Fig. 3C) , as was type D (Fig. 3D ), although there were few patients with D (7 patients with score 1 and 3 patients with score 2; only score 2 showed decreased survival). Cases with both types C and E were frequent (Fig. 2F ).
IgD expression was found in LP cells in 65 of 130 tested (50%) (Fig. 4A) , was not associated with outcome, but was positively correlated with types C and E histology (P < 0.0001), and negatively correlated with types A (P = 0.003) and B (P = 0.0059) (Fig. 5) . 
DISCUSSION
NLPHL is an uncommon disease that is frequently indolent and often cured with chemotherapy and/or RT regimens designed for CHL. Such treatment, however, poses long-term risks and efforts have been made to reduce therapy in children while preserving good therapeutic outcomes. This is particularly important in NLPHL, since some patients have been cured with local therapy such as resection alone. COG protocol AHOD03P1 tested whether excellent outcomes could be preserved in patients with low-risk NLPHL by resection alone or minimal chemotherapy, and the results appear to be very good. 1 Some patients with NLPHL may demonstrate a more aggressive course than usual, with relapse following therapy or transformation to B-cell non-Hodgkin lymphoma; thus, efforts have been made to identify prognostic factors. 17, 18 Presence or absence of CD30 expression has been utilized to help distinguish between NLPHL and CHL, variation in histology has been studied, and IgD expression has also been examined. 6, 7, 9, 16 A few studies have noted that some cases of NLPHL express CD30, usually in weak and/or focal patterns, and that the morphology and immunophenotype of these is similar to CD30-negative cases. 11, 12 A rare case of relapsed NLPHL with CD30 expression showed response to brentuximab vedotin, a chimeric anti-CD30 monoclonal antibody conjugate that is widely used for refractory CHL. 15 Huppmann et al.
in a large study of adult and pediatric NLPHL, reported that 3-5%
expressed EBER transcripts and that these more frequently expressed CD30 than did EBV-negative cases. 13 In our current study, only one CD30-positive case was found to express EBER. CD30-negative cases were not tested for EBER. from 118 patients with NLPHL and described the six patterns utilized in this study. 6 Histologic subtypes overlapped in their study and there were no cases of pure type C or pure diffuse type E. Our findings are similar in these regards. In their study, 16 cases were predominantly diffuse while 19 showed a minor component of diffuse (total = 35). Ten cases showed a predominant pattern of type C and 41 showed presence of a minor component (total = 51). Thus, 43%
showed some type C pattern, compared to 63% of our pediatric cases. Twenty-three percent were treated with surgery alone, 67% with CVP chemotherapy, and 10% with other chemotherapy. There was a notably lower proportion of type C in their study than in our study, with most variants being diffuse (23% total variant histology).
Compared to our results that found IgD expression in 64 of 130 cases (49%), a study by Prakash et al. identified 27% IgD-positive patients. 16 Median age in that study was 38 years (range 7-81 years).
They demonstrated that IgD expression was associated with younger age, male predominance, cervical lymph node involvement, and prominent extranodular localization of LP cells (type C). Recently, Hartmann et al. also evaluated the prognostic role of several additional histologic features in NLPHL and showed no association between IgD and outcome. 7 Seven of eight IgD-positive cases showed type C histology.
Variant histology in NLPHL is currently being included in an updated revision of the WHO classification, based on the findings of association with advanced disease and relapse. 20 In our study, the most frequent histologic types were A, B, C, and E, and all combinations of these ( Fig. 2F and Fig. 6 ). an early form of this progression, and that NLPHL and DLBCL may be related. 6 Xing et al. argue that the outcome of NLPHL is largely stagerelated and that therapy usually applied to DLBCL may be optimal for relapsed NLPHL. 21 In their study, relapses of NLPHL included cases was too small to draw conclusions. Our study suggests that delineation of variant histology and performance of IgD staining may be helpful to identify patients for whom increased surveillance may be indicated, however, the outcome of the study remains excellent. Overall survival is 100% and variant histology does not imply that limited therapy is contraindicated if clinical follow-up is adequate.
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